Reports on biosimilar medicines

18

Meitheamh 2024

0

Proposal for the Creation of the National Observatory of Biosimilar Medicines

27

February 2024

0

Study on the market for biosimilar medicines in the National Health System in Spain

Feb 27 2024 BioSim (EN) Biosim

02

Deireadh Fómhair 2023

0

Report on savings on generic and biosimilar drugs in the US.

October 02 2023 Other entities Biosim

28

Meitheamh 2023

0

“Early Treatment”: The role of biosimilars

28 June 2023 BioSim (EN) Biosim

15

May 2023

0

EMA Annual Report 2022

15 May 2023 Other entities Biosim

04

December 2022

0

Monograph "Real world evidence: Abstract library"

04 2022 December Other entities Biosim

10

November 2022

0

Biosimilars: innovation from sustainability

November 10 2022 BioSim (EN) Biosim

04

Deireadh Fómhair 2022

0

Trends in the field of biosimilars in the United States

October 04 2022 Other entities Biosim

04

Sep 2022

0

Analysis of US Health Savings from Generics and Biosimilars in 2021

04 September 2022 Other entities Biosim

24

February 2022

0

Biosimilars in the new National Health System: Proposals for action

Feb 24 2022 BioSim (EN) Biosim

24

February 2022

0

Biosimilars within the new Spanish National Health System. Proposals for action

Feb 24 2022 BioSim Biosim

30

November 2021

0

Public procurement of biosimilar medicines in the National Health System

November 30 2021 BioSim (EN) Biosim

15

November 2021

0

Improving Understanding and Acceptance of Biosimilars in the United States

November 15 2021 Other entities Biosim

03

November 2021

0

Biosimilars in the treatment of solid tumors

November 03 2021 Other entities Biosim

19

Deireadh Fómhair 2021

0

The US Generic & Biosimilar Medicines Savings Report

October 19 2021 Other entities Biosim

01

July 2021

0

Biennial Report of BioSim Activities 2019-2020

Jul 01 2021 BioSim (EN) Biosim

24

Márta 2021

0

Basis for a biosimilar gainsharing project

March 24 2021 BioSim (EN) Biosim

05

Jan 2021

0

Education in Biosimilars - Whitepaper

Jan 05 2021 Other entities Biosim

27

November 2020

0

Clinical management, incentives and biosimilars

November 27 2020 BioSim (EN) Biosim

27

November 2020

0

Budget impact analysis of biosimilar medicines in the Spanish National Health System (2009-2022)

November 27 2020 BioSim (EN) Biosim

18

November 2020

0

What do we know about biosimilar biologics?

November 18 2020 Other entities Biosim

18

November 2020

0

Communication in biosimilar biologics

November 18 2020 Other entities Biosim

17

November 2020

0

Variability in the adoption of biosimilars

November 17 2020 Other entities Biosim

15

Deireadh Fómhair 2020

0

Hospital expenditure of the National Health System: pharmacy and investment in capital goods

October 15 2020 Other entities Biosim

14

Deireadh Fómhair 2020

0

Biosimilars in the United States 2020–2024 COMPETITION, SAVINGS, AND SUSTAINABILITY

October 14 2020 Other entities Biosim

07

Deireadh Fómhair 2020

0

Biosimilars, for value-based healthcare

October 07 2020 Other entities Biosim

29

Meitheamh 2020

0

Country Scorecards for Biosimilar Sustainability

29 June 2020 Other entities Biosim

02

Deireadh Fómhair 2019

0

Biosimilars in the European Union

October 02 2019 Other entities Biosim

01

May 2019

0

The principle of justice and biosimilar medicines in the National Health System (SNS)

01 May 2019 BioSim (EN) Biosim

12

July 2018

0

Biosimilars Action Plan: Balancing Innovation and Competition

Jul 12 2018 Other entities Biosim

19

July 2017

0

Biosimilars: new ways to innovate

Jul 19 2017 BioSim (EN) Biosim

01

July 2016

0

What do I need to know about Biosimilar Medicines. Information for patients.

Jul 01 2016 Other entities Biosim

14

July 2013

0

What you should know about biosimilar medicines. European Commission Consensus Report

Jul 14 2013 Other entities Biosim

Reports

Proposal for the Creation of the National Observatory of Biosimilar Medicines

Study on the market for biosimilar medicines in the National Health System in Spain

Report on savings on generic and biosimilar drugs in the US.

“Early Treatment”: The role of biosimilars

EMA Annual Report 2022

Monograph "Real world evidence: Abstract library"

Biosimilars: innovation from sustainability

Trends in the field of biosimilars in the United States

Analysis of US Health Savings from Generics and Biosimilars in 2021

Biosimilars in the new National Health System: Proposals for action

Biosimilars within the new Spanish National Health System. Proposals for action

Public procurement of biosimilar medicines in the National Health System

Improving Understanding and Acceptance of Biosimilars in the United States

Biosimilars in the treatment of solid tumors

The US Generic & Biosimilar Medicines Savings Report

Biennial Report of BioSim Activities 2019-2020

Basis for a biosimilar gainsharing project

Education in Biosimilars - Whitepaper

Clinical management, incentives and biosimilars

Budget impact analysis of biosimilar medicines in the Spanish National Health System (2009-2022)

What do we know about biosimilar biologics?

Communication in biosimilar biologics

Variability in the adoption of biosimilars

Hospital expenditure of the National Health System: pharmacy and investment in capital goods

Biosimilars in the United States 2020–2024 COMPETITION, SAVINGS, AND SUSTAINABILITY

Biosimilars, for value-based healthcare

Country Scorecards for Biosimilar Sustainability

Biosimilars in the European Union

The principle of justice and biosimilar medicines in the National Health System (SNS)

Biosimilars Action Plan: Balancing Innovation and Competition

Biosimilars: new ways to innovate

What do I need to know about Biosimilar Medicines. Information for patients.

What you should know about biosimilar medicines. European Commission Consensus Report

ABOUT BIOSIM

ABOUT BIOSIMILARS

BioSim Newsletter